🚀 VC round data is live in beta, check it out!
Nyxoah Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nyxoah and similar public comparables like EKF Diagnostics, AMJ Global Technology, Guerbet, AVITA Medical and more.
Nyxoah Overview
About Nyxoah
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Founded
2009
HQ
Employees
184
Website
Financials (LTM)
EV
$134M
Nyxoah Financials
Nyxoah reported last 12-month revenue of $19M and negative EBITDA of ($93M).
In the same LTM period, Nyxoah generated $12M in gross profit, ($93M) in EBITDA losses, and had net loss of ($104M).
Revenue (LTM)
Nyxoah P&L
In the most recent fiscal year, Nyxoah reported revenue of $12M and EBITDA of ($89M).
Nyxoah expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $19M | XXX | $12M | XXX | XXX | XXX |
| Gross Profit | $12M | XXX | $7M | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | ($93M) | XXX | ($89M) | XXX | XXX | XXX |
| EBITDA Margin | (481%) | XXX | (758%) | XXX | XXX | XXX |
| EBIT Margin | (504%) | XXX | (818%) | XXX | XXX | XXX |
| Net Profit | ($104M) | XXX | ($104M) | XXX | XXX | XXX |
| Net Margin | (536%) | XXX | (880%) | XXX | XXX | XXX |
| Net Debt | — | — | $11M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nyxoah Stock Performance
Nyxoah has current market cap of $143M, and enterprise value of $134M.
Market Cap Evolution
Nyxoah's stock price is $3.27.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $134M | $143M | 0.0% | XXX | XXX | XXX | $-2.38 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNyxoah Valuation Multiples
Nyxoah trades at 6.9x EV/Revenue multiple, and (1.4x) EV/EBITDA.
EV / Revenue (LTM)
Nyxoah Financial Valuation Multiples
As of April 20, 2026, Nyxoah has market cap of $143M and EV of $134M.
Equity research analysts estimate Nyxoah's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nyxoah has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $143M | XXX | $143M | XXX | XXX | XXX |
| EV (current) | $134M | XXX | $134M | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | (1.4x) | XXX | (1.5x) | XXX | XXX | XXX |
| EV/EBIT | (1.4x) | XXX | (1.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 10.7x | XXX | 18.0x | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | (1.5x) | XXX | (1.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nyxoah Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nyxoah Margins & Growth Rates
Nyxoah's revenue in the last 12 month grew by 164%.
Nyxoah's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Nyxoah's rule of 40 is (50%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nyxoah's rule of X is 282% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Nyxoah Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 164% | XXX | 221% | XXX | XXX | XXX |
| EBITDA Margin | (481%) | XXX | (758%) | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 15% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (50%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 282% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 463% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 248% | XXX | 427% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 891% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nyxoah Public Comps
See public comps and valuation multiples for other Medical Devices and Digital Therapeutics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nyxoah | XXX | XXX | XXX | XXX | XXX | XXX |
| EKF Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| AMJ Global Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Guerbet | XXX | XXX | XXX | XXX | XXX | XXX |
| AVITA Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Paxman | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nyxoah M&A Activity
Nyxoah acquired XXX companies to date.
Last acquisition by Nyxoah was on XXXXXXXX, XXXXX. Nyxoah acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nyxoah
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNyxoah Investment Activity
Nyxoah invested in XXX companies to date.
Nyxoah made its latest investment on XXXXXXXX, XXXXX. Nyxoah invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nyxoah
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nyxoah
| When was Nyxoah founded? | Nyxoah was founded in 2009. |
| Where is Nyxoah headquartered? | Nyxoah is headquartered in Belgium. |
| How many employees does Nyxoah have? | As of today, Nyxoah has over 184 employees. |
| Who is the CEO of Nyxoah? | Nyxoah's CEO is Olivier Taelman. |
| Is Nyxoah publicly listed? | Yes, Nyxoah is a public company listed on Euronext Brussels. |
| What is the stock symbol of Nyxoah? | Nyxoah trades under NYXH ticker. |
| When did Nyxoah go public? | Nyxoah went public in 2021. |
| Who are competitors of Nyxoah? | Nyxoah main competitors are EKF Diagnostics, AMJ Global Technology, Guerbet, AVITA Medical. |
| What is the current market cap of Nyxoah? | Nyxoah's current market cap is $143M. |
| What is the current revenue of Nyxoah? | Nyxoah's last 12 months revenue is $19M. |
| What is the current revenue growth of Nyxoah? | Nyxoah revenue growth (NTM/LTM) is 164%. |
| What is the current EV/Revenue multiple of Nyxoah? | Current revenue multiple of Nyxoah is 6.9x. |
| Is Nyxoah profitable? | No, Nyxoah is not profitable. |
| What is the current EBITDA of Nyxoah? | Nyxoah has negative EBITDA and is not profitable. |
| What is Nyxoah's EBITDA margin? | Nyxoah's last 12 months EBITDA margin is (481%). |
| What is the current EV/EBITDA multiple of Nyxoah? | Current EBITDA multiple of Nyxoah is (1.4x). |
| What is the current FCF of Nyxoah? | Nyxoah's last 12 months FCF is ($89M). |
| What is Nyxoah's FCF margin? | Nyxoah's last 12 months FCF margin is (459%). |
| What is the current EV/FCF multiple of Nyxoah? | Current FCF multiple of Nyxoah is (1.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.